ReviewFEMS microbiology letters2008
Animal models of mucosal Candida infection.
Review in FEMS microbiology letters, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed.
- Nanomedicine in the Topical Management of Vulvovaginal Candidiasis: An Overview of In Vivo Data.Journal of fungi (Basel, Switzerland) · 2026Review
- Anatomopathological uterine findings ofJournal of medical microbiology · 2026Article
- Innovative simvastatin-loaded emulgel effectively treats vulvovaginal candidiasis: in vivo efficacy and in vitro biopharmaceutical analysis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Comparative analysis of two immunosuppression protocols for vulvovaginal candidiasis induction in Wistar rats.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Candida albicans migrates itself from the vagina to the uterus and ovaries in estrogenized mice.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Article
- Molecular mechanisms of neutrophil regulatory network in anti-Candida infection.Frontiers in immunology · 2025Review
- Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.Cell host & microbe · 2024Review
- Longitudinal gut fungal alterations and potential fungal biomarkers for the progression of primary liver disease.Science China. Life sciences · 2024Article
- Chitosan nanoparticles encapsulating farnesol evaluated in vivo against Candida albicans.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Major Histocompatibility Complex II Expression on Oral Langerhans Cells Differentially Regulates Mucosal CD4 and CD8 T Cells.The Journal of investigative dermatology · 2024Article
- The Underrated Gut Microbiota Helminths, Bacteriophages, Fungi, and Archaea.Life (Basel, Switzerland) · 2023Review
- Molecular association ofFrontiers in cellular and infection microbiology · 2023Review
- Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm ofInternational journal of molecular sciences · 2022Article
- Trans-cellular tunnels induced by the fungal pathogen Candida albicans facilitate invasion through successive epithelial cells without host damage.Nature communications · 2022Article
- Caenorhabditis elegans DAF-16 regulates lifespan and immune responses to Cryptococcus neoformans and Cryptococcus gattii infections.BMC microbiology · 2022Article
- A Denture Use Model Associated withJournal of fungi (Basel, Switzerland) · 2022Article
- The Role of IL-17 During Infections in the Female Reproductive Tract.Frontiers in immunology · 2022Review
- Methods Related to the Immunopathogenesis of Vulvovaginal Candidiasis and Associated Neutrophil Anergy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Rodent models of oral, vaginal and gastrointestinal Candida infection are described and discussed in terms of their scientific merits. The common feature of all experimental mucosal Candida infections is the need for some level of host immunocompromise or exogenous treatment to ensure quantitatively reproducible disease. A growing literature describes the contributions of such candidiasis models to our understanding of certain aspects of fungal virulence and host response to mucosal Candida albicans challenge. Evidence to date shows that T-lymphocyte responses dominate host immune defences to oral and gastrointestinal challenge, while other, highly compartmentalized responses defend vaginal surfaces. By contrast the study of C. albicans virulence factors in mucosal infection models has only begun to unravel the complex of attributes required to define the difference between strongly and weakly muco-invasive strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.